PASSAGE BIO, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $9.00K, a 80.85% decline year-over-year.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $14.00K, a 72.00% decline year-over-year.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $47.00K, a 2.17% increase year-over-year.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $135.00K, a 55.59% decline from fiscal 2022.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $304.00K, a 65.73% decline from fiscal 2021.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $887.00K, a 212.32% increase from fiscal 2020.
- PASSAGE BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $284.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $9.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $23.00K S-4/A · filed 2026-09-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-10 | |
| 2025-06-30 | $14.00K S-4/A · filed 2026-09-03 | |
| 2024-12-31 | $47.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $97.00K S-4/A · filed 2026-09-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $50.00K 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $135.00K 10-K · filed 2025-03-04 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2023-06-30 | $89.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $304.00K 10-K · filed 2024-03-04 |
| 2022-09-30 | $79.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $243.00K 10-Q · filed 2023-08-07 | |
| 2021-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $887.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-06-30 | $505.00K 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $284.00K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |